Alzeca Biosciences
Houston
About Alzeca Biosciences
Alzeca Biosciences develops novel advanced imaging agents for the early diagnosis of neurodegenerative diseases, including Alzheimer’s Disease. Alzheimer’s affects approximately 5.5M Americans at a cost of over $226 billion in care, and affects over 27 million patients worldwide. Its incidence is projected to quadruple by 2050 with costs exceeding $1 trillion in the US alone, unless a more effective diagnostic and treatment method is achieved.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $10K – $50K
- Total funding: $11.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Oct 2019)
- Website: alzeca.com
Industries & Categories
Biotechnology, Health Care, Health Diagnostics
Social Profiles
Canonical: https://fsome.com/organization/alzeca-biosciences-72062 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.